ThermoFisher： full-year revenue of $24.36 billion, increased by 16%
 
　　——Strong acquisitions drive growth
 
ThermoFisher Scientific, which has seen strong revenue growth as ever.According to the financial report, ThermoFisher took in $24.36 billion in 2018, up 16% from $20.92 billion in 2017.Organic revenues grew 8%, acquisitions boosted revenue by 7% and monetary effects contributed 1%.Full-year net income was $2.94 billion, up from $2.22 billion in 2017.In addition, research and development expenses increased 9% to $967 million from $887 million.　

ThermoFisher has made at least four acquisitions in the past year.From DNA platform, SEM/ imaging/analysis software to electron microscope and advanced biological process, they are all hot fields in the current industry. Acquisitions have proven to strengthen ThermoFisher's position in different areas of expertise and contribute significantly to annual revenue growth. 
In terms of the performance of various departments in 2018, the laboratory products and services department increased by 28% from $7.83 billion last year to $10.04 billion, which was the most eye-catching in terms of both total revenue and growth rate.Second, ThermoFisher's life science solutions division, which has been pushing hard in recent years, grew 9% to $6.27 billion from $5.73 billion, a growth rate that needs to be further stimulated.In addition, the revenue of the analytical instruments division increased by 13% from $4.82 billion to $5.47 billion, and that of the professional diagnosis division increased by 7% from $3.49 billion to $3.72 billion, with both businesses performing well.Revenue is expected to range from $24.88 billion to $25.28 billion in 2019, up 2% to 4% from $24.36 billion in 2018.Of course, this estimate is relatively conservative, as can be seen from the previous growth rate of more than 10%.　
 
 Agilent: full-year revenue of $4.91 billion, increased by 10%
 
　　——Three groups are doing well

Unlike its peers, Agilent's annual results are set on October 31.Agilent was the first to disclose its fiscal 2018 financial results on Nov. 19, 2018. Agilent reported full-year revenue of $4.91 billion, up 10%, with core revenue up 7%.Annual net income was $316 million.
In 2018, the revenue of Agilent's three major groups showed rapid growth.Among them, life sciences and applied markets group achieved strong growth in all major end markets, platforms and regions, with revenue of $2.3 billion, up 9% annually.CrossLab group full-year revenue of $1.7 billion, up 11% from a year earlier, with a strong performance in its services and consumables business.The diagnostics and genetics group reported $943 million in revenue, up 10% annually.The growth of the pharmaceutical industry and the rapidly growing demand for genes, NASD products have played a leading role.According to the company information, the outstanding performance of the fourth quarter is helpful for Agilent's full-year results.Since becoming an independent life sciences company in 2014, Agilent has achieved its highest annual core growth rate and profitability in fiscal 2018.The result has been solid growth in legacy businesses, portfolio enhancements from multiple acquisitions and share buybacks.For 2019, Agilent expects full-year revenue to be between $5.13 billion and $5.17 billion, up 4.4% to 5.2%.
 
PerkinElmer： full-year revenue of $2.78 billion, increased by 23%
 
　　——2018 is the new turning point

 PerkinElmer's revenue grew 23%in 2018, compared with $2.26 billion in 2017, to pull in a good $2.78 billion.This exciting performance has undoubtedly benefited from the rapid growth of the diagnostic business, exploration and analysis solutions (DAS) business.Diagnostics, in particular, saw revenues jump by 60% to $1.08 billion.The exploration and analysis solutions (DAS) business contributed $1.69bn, up 7% year-on-year.
It is revealed that in the future, PerkinElmer will pay more attention to some factors that may affect the development of performance, including the decline of market share or the failure to grow as expected, the fluctuation of global economic and political environment, the failure to launch new products, the failure to adequately protect intellectual property rights and so on.We believe that 2018 will be a turning point for PerkinElmer's overall development and lay a good foundation for the development in 2019 and beyond.　　
 
 Waters： full-year revenue of $2.44 billion, increased by 4%
 
　　——Chinese market is doing well
 

Waters recently released its 2018 financial report, showing full-year revenue of $2.44 billion, up 4% from a year earlier.Corporate gross margins rose 59%, operating margins 31% and tax rates 13%.Notably, the company raked in $440 million in China last year, up 12% from $380 million in 2017.

In terms of business development, the consumables and service products of Waters brand instruments and software platform increased by 3% in total in 2018, the instruments and services of TA instrument brand increased by 7% in total, and the products increased by 4% in pharmaceutical, industrial and government/academic fields.Annual revenue growth is expected to be between 4% and 6% between 2019 and 2021, which is fairly solid.In the future, Waters will continue to develop the pharmaceutical industry, and promote the growth of the company's revenue through the development of new products and the expansion of the Chinese market.